Issuance of common stock in connection with achievement of regulatory approval milestone, net of issuance costs (Shares)

[Table](#i6fa56528b8724eb3888e814d9e0a196b_7) [of](#i6fa56528b8724eb3888e814d9e0a196b_7) [Contents](#i6fa56528b8724eb3888e814d9e0a196b_7)

|  |  |  |
| --- | --- | --- |
|  |  |  |
| DexCom, Inc. |
| Consolidated Statements of Stockholders’ Equity |
| (Unaudited) |



|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |
|  |  | Nine Months Ended September 30, 2022 |
| (In millions) |  | Common Stock |  | AdditionalPaid-InCapital |  | Accumulated Other Comprehensive Income (Loss) |  | Retained Earnings |  | Treasury Stock |  | TotalStockholders’Equity |
| Shares |  | Amount |  |
| Balance at December 31, 2021 (As Adjusted)\* |  | 388.0  |  |  | $ | 0.4  |  |  | $ | 2,108.7  |  |  | $ | 0.5  |  |  | $ | 138.7  |  |  | $ | (206.2) |  |  | $ | 2,042.1  |  |
| Issuance of common stock under equity incentive plans |  | 1.5  |  |  | —  |  |  | —  |  |  | —  |  |  | —  |  |  | —  |  |  | —  |  |
| Issuance of common stock for Employee Stock Purchase Plan |  | 0.3  |  |  | —  |  |  | 22.5  |  |  | —  |  |  | —  |  |  | —  |  |  | 22.5  |  |
| Issuance of common stock in connection with achievement of regulatory approval milestone, net of issuance costs |  | 2.9  |  |  | —  |  |  | (189.3) |  |  | —  |  |  | —  |  |  | 189.2  |  |  | (0.1) |  |
| Purchases of treasury stock |  | (6.6) |  |  | —  |  |  | —  |  |  | —  |  |  | —  |  |  | (557.7) |  |  | (557.7) |  |
| Conversions of 2023 Notes |  | 0.4  |  |  | —  |  |  | 4.2  |  |  | —  |  |  | —  |  |  | 13.2  |  |  | 17.4  |  |
| Benefit of note hedge upon conversions of 2023 Notes |  | (0.3) |  |  | —  |  |  | 33.5  |  |  | —  |  |  | —  |  |  | (33.5) |  |  | —  |  |
| Share-based compensation expense |  | —  |  |  | —  |  |  | 92.5  |  |  | —  |  |  | —  |  |  | —  |  |  | 92.5  |  |
| Net income |  | —  |  |  | —  |  |  | —  |  |  | —  |  |  | 249.4  |  |  | —  |  |  | 249.4  |  |
| Other comprehensive loss, net of tax |  | —  |  |  | —  |  |  | —  |  |  | (41.6) |  |  | —  |  |  | —  |  |  | (41.6) |  |
| Balance at September 30, 2022 |  | 386.2  |  |  | $ | 0.4  |  |  | $ | 2,072.1  |  |  | $ | (41.1) |  |  | $ | 388.1  |  |  | $ | (595.0) |  |  | $ | 1,824.5  |  |

  


|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | Nine Months Ended September 30, 2021 |
| (In millions) |  | Common Stock |  | AdditionalPaid-InCapital |  | Accumulated Other Comprehensive Income |  | Retained Earnings (Accumulated Deficit) |  | Treasury Stock |  | TotalStockholders’Equity |
| Shares |  | Amount |  |
| Balance at December 31, 2020 (As Adjusted)\* |  | 384.4  |  |  | $ | 0.4  |  |  | $ | 1,726.5  |  |  | $ | 3.2  |  |  | $ | (78.2) |  |  | $ | (100.0) |  |  | $ | 1,551.9  |  |
| Issuance of common stock under equity incentive plans |  | 2.8  |  |  | —  |  |  | —  |  |  | —  |  |  | —  |  |  | —  |  |  | —  |  |
| Issuance of common stock for Employee Stock Purchase Plan |  | 0.2  |  |  | —  |  |  | 20.3  |  |  | —  |  |  | —  |  |  | —  |  |  | 20.3  |  |
| Tax benefit related to Senior Convertible Notes |  | —  |  |  | —  |  |  | —  |  |  | —  |  |  | —  |  |  | —  |  |  | —  |  |
| Conversions of 2023 Notes |  | 0.8  |  |  | —  |  |  | 26.7  |  |  | —  |  |  | —  |  |  | 5.6  |  |  | 32.3  |  |
| Benefit of note hedge upon conversions of 2023 Notes |  | (0.5) |  |  | —  |  |  | 65.1  |  |  | —  |  |  | —  |  |  | (65.1) |  |  | —  |  |
| Share-based compensation expense |  | —  |  |  | —  |  |  | 87.1  |  |  | —  |  |  | —  |  |  | —  |  |  | 87.1  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Net income |  | —  |  |  | —  |  |  | —  |  |  | —  |  |  | 222.2  |  |  | —  |  |  | 222.2  |  |
| Other comprehensive loss, net of tax |  | —  |  |  | —  |  |  | —  |  |  | (1.8) |  |  | —  |  |  | —  |  |  | (1.8) |  |
| Balance at September 30, 2021 (As Adjusted)\* |  | 387.7  |  |  | $ | 0.4  |  |  | $ | 1,925.7  |  |  | $ | 1.4  |  |  | $ | 144.0  |  |  | $ | (159.5) |  |  | $ | 1,912.0  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| \* We adjusted our 2021 amounts to reflect the simplified convertible instruments accounting guidance, which we adopted on a full retrospective basis. All periods presented have been adjusted to reflect the four-for-one stock split. Refer to Note 1, “Organization and Significant Accounting Policies,” for further information. |

See accompanying notes7
